Pedometer and Exercise Study in Prostate Cancer Patients With Hormonal Therapy

• 18 years of age or older
• Histologically proven prostate cancer
• Treatment plan is to administer long term ADT (androgen deprivation therapy).
• Patient must currently be treated with ADT for at least 2 weeks before enrollment in trial, and for no more than 6 months. Patient treated with a maximum androgen blockade strategy, combining an anti-androgen agent with a LHRH analog agent are admissible to this protocol, but not patients treated only with an anti-androgen agent alone.
• Written informed consent to participate in the trial.

Exclusion Criteria:

• Known hypersensitivity to Zoladex, Casodex (if applicable), or any component of these product, or to other similar agents
• Severe cardiac disease (New York Heart Association class III or greater)
• Severe lung disease
• Uncontrollable pain
• Unstable bone lesion
• Any co-morbidity restraining the patient's ability to walk alone or to modify his walking habits (eg Parkinson's disease, advanced multiple sclerosis, leg amputation, ...)
• Any concomitant condition that would make it undesirable, in the physician's opinion, for the subject to participate in the trial or would jeopardize compliance with the protocol.
• Any contraindication to undertake the 6-minutes walk test (unstable angina or myocardial infarction during the previous month, a resting heart rate of more than 180, systolic blood pressure of more than 180, and a diastolic pressure of more than 100). The patient must have his cardiovascular conditions stabilized and controlled before enrollment in the trial.
• Unwillingness or incapacity to consent to trial participation.